obesity

News

Novo Nordisk weakens again on interim results readout

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the first half of this year.

News

Noom Med app and accompanying GLP-1 implements

Noom expands its GLP-1 range with 'microdose' package

Noom is offering 'microdoses' of semaglutide at a knock-down price, claiming they can prevent side effects but remain effective for weight loss.

News

NICE calls for better care after weight-loss therapy ends

People completing a course of obesity medication, or completing a weight-management programme, need better support, according to NICE.

News

Novo Nordisk slumps as it cuts sales forecast, names new CEO

Novo Nordisk has a new CEO, facing an uphill battle to restore the fortunes of its US business as diabetes and obesity drugs come under pressure.

News

Hengrui to file obesity shot in China after phase 3 win

An obesity therapy developed by Hengrui Pharma and Kailera is being prepared for its first regulatory submission, in China.

News

Novo Nordisk files high-dose Wegovy in EU

Novo Nordisk has moved quickly to file for approval of a higher-dose version of obesity drug Wegovy as it fends off stiff competition from Eli Lilly.

Novo Nordisk weakens again on interim results readout

Noom expands its GLP-1 range with 'microdose' package

NICE calls for better care after weight-loss therapy ends

Novo Nordisk slumps as it cuts sales forecast, names new CEO

Hengrui to file obesity shot in China after phase 3 win

Novo Nordisk files high-dose Wegovy in EU

UK, pharma industry pilot rapid access routes for medicines

Discover a new era of healthcare panel engagement: Grounded ...

obesity

Editor's Picks